tuesday biolinerx announc result provid busi updat within
next month expect see result lead-in cohort patient
enrol phase genesi trial investig stem cell mobil
autolog transplant view genesi studi compani primari
valu driver believ data separ trial evalu single-
agent mobil allogen transplant set slate present eha
could de-risk genesi lead-in cohort readout later expect see
earli result one on-going morpheu studi cohort evalu
variou cancer well initi first-in-human trial
reiter outperform pt
lead-in cohort genesi enrol multipl myeloma patient
treat mg/kg g-csf slightli higher maximum
dose test prior phase trial g-csf
show dose-depend improv stem cell yield assum posit
lead-in cohort result patient random receiv g-
csf g-csf alon
last week compani announc result phase trial
investig allogen transplant would present eha next
month per abstract singl mg/kg dose led
success stem cell mobil donor believ result
could partial de-risk mg/kg dose use genesi
expect see earli data one
morpheu cohort investig combin atezolizumab
aml pancreat gastric cancer januari compani present
immunolog evid separ trial combat pancreat cancer
show increas tumor-infiltr t-cell may
prerequisit anti-tumor immun
compani second oncolog asset prepar enter
clinic inject intratumor design co-
opt pre-exist anti-alpha-g antibodi tag tumor immune-medi
potenti melanoma
compani report net loss less estim
biolinerx end cash equival estim
could sustain oper late expect modest increas
expenditur enter clinic updat estim
anticip quarterli burn remaind
clinical-stag bio-
pharmaceut compani focus
hematolog malign
analyst certif import disclosur see disclosur
rate blrx outperform pt
base risk-adjust revenu ep multipl analysi
valuat base commerci potenti
auto-hsct mobil believ result phase
genesi trial could spur major transplant physician
choos mozobil combin g-csf drug
approv upsid thesi includ use allo-
hsct aml solid tumor compani boast catalyst-
rich deep oncolog pipelin attract collabor
novarti merck genentech
genesi readout patient multipl myeloma mm
undergo auto-hsct fda approv
success bridg studi expand label auto-hsct non-
risk-adjust peak market stem cell
mobil us eu market
potenti result lead-in genesi cohort
potenti top-lin result phase studi use
potenti pancreat cancer phase
potenti interim readout phase morpheu studi
solid tumor
potenti interim readout on-going blast studi
better expect uptak mobil auto-hsct
expans allo-hsct
clinic success blast and/or battl trial
potenti lead approv aml
clinic success use solid tumor
clinic success earli stage program
clinical/regulatori failur auto-hsct uptak
auto-hsct
compani pursu label expans nhl
limit on-label use patient mm
price target per share deriv discount project revenu ep risk-
adjust target multipl line histor multipl profit biotech compani given current stage
develop stem cell mobil project potenti launch
risk includ clinic regulatori financ competit market price pressur note view blrx stock
trade specul appropri risk-toler investor
stem cell mobil
potenti result lead-in genesi cohort
potenti top-line result investig sponsor trial allogen stem cell
solid tumor aml
potenti interim result studi pancreat cancer
initi phase cohort atezolizumab combin nsclc
potenti interim readout blast studi aml consolid
potenti top-line result trial
potenti interim readout phase studi atezolizumab solid tumor
solid tumor
potenti initi phase monotherapi studi solid tumor
compani present oppenheim co
sec file oppenheim co research
figur thousand except per share stem cell mobil expens good sold research develop sale market gener administr oper incom incom loss incom incom incom loss attribut common per share share outstand co inc mark breidenbach blrx outperform
sec file oppenheim co research
figur thousand except per share cash short-term bank prepaid current long-term prepaid long-term properti equip intang asset non-curr current matur long-term bank account payabl accrual current long-term bank loan net current non-curr equiti ordinari share capit comprehens accumul stockhold liabil stockhold co inc mark breidenbach biolinerx
stock price compani mention report
